HRT Financial’s Acceleron Pharma XLRN Stock Holding History

HRT Financial’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,119	Closed	-$1.27M	–	3976
2021 Q2	$1.27M	Buy	+10,119	New	+$1.28M	0.01%	874
2020 Q4	–	Sell	-27,110	Closed	-$3.05M	–	2746
2020 Q3	$3.05M	Sell	27,110 -11,709	-30%	-$1.17M	0.09%	160
2020 Q2	$3.7M	Buy	+38,819	New	+$3.74M	0.11%	180
2019 Q3	–	Sell	-5,248	Closed	-$215K	–	1677
2019 Q2	$215K	Buy	+5,248	New	+$217K	0.01%	617

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

HRT Financial's XLRN Position: Q3 2021 in Review

HRT Financial sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 10,119 shares — an estimated $1.27M sold.

HRT Financial first reported a position in XLRN in Q2 2019 and held it in 4 quarters. The position peaked at $3.7M in Q2 2020. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

HRT Financial reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
HRT Financial sold 10,119 Acceleron Pharma shares in Q3 2021, an estimated $1.27M.
HRT Financial first reported a position in Acceleron Pharma in Q2 2019 and held it in 4 quarters.
HRT Financial's Acceleron Pharma position peaked at $3.7M in Q2 2020.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on HRT Financial's 13F filing for Q3 2021, filed 15 Nov 2021.